Insulin growth factor 2 (IGF2) as an emergent target in psychiatric and neurological disorders. Review.
Alzheimer
Cognitive disabilities
Insulin growth factor 2
Memory
PTSD
Schizophrenia
Journal
Neuroscience research
ISSN: 1872-8111
Titre abrégé: Neurosci Res
Pays: Ireland
ID NLM: 8500749
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
02
08
2018
revised:
05
10
2018
accepted:
29
10
2018
pubmed:
6
11
2018
medline:
21
5
2020
entrez:
4
11
2018
Statut:
ppublish
Résumé
Insulin-like growth factor 2 (IGF2) is abundantly expressed in the central nervous system (CNS). Recent evidence highlights the role of IGF2 in the brain, sustained by data showing its alterations as a common feature across a variety of psychiatric and neurological disorders. Previous studies emphasize the potential role of IGF2 in psychiatric and neurological conditions as well as in memory impairments, targeting IGF2 as a pro-cognitive agent. New research on animal models supports that upcoming investigations should explore IGF2's strong promising role as a memory enhancer. The lack of effective treatments for cognitive disturbances as a result of psychiatric diseases lead to further explore IGF2 as a promising target for the development of new pharmacology for the treatment of memory dysfunctions. In this review, we aim at gathering all recent relevant studies and findings on the role of IGF2 in the development of psychiatric diseases that occur with cognitive problems.
Identifiants
pubmed: 30389571
pii: S0168-0102(18)30435-8
doi: 10.1016/j.neures.2018.10.012
pii:
doi:
Substances chimiques
IGF2 protein, human
0
Insulin-Like Growth Factor II
67763-97-7
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-13Informations de copyright
Published by Elsevier B.V.